The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFPß), including TGFß1, TGFß2 and TGFß3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFß expression.
